172 related articles for article (PubMed ID: 34797106)
21. Experiences of women on the use of Implanon NXT in Gauteng province, South Africa: A qualitative study.
Ntimani JM; Randa MB
Health SA; 2024; 29():2237. PubMed ID: 38445029
[TBL] [Abstract][Full Text] [Related]
22. Early Implanon discontinuation rate and its associated factors in health institutions of Mekelle City, Tigray, Ethiopia 2016/17.
G/Medhin T; Gebrekidan KG; Nerea MK; Gerezgiher H; Haftu M
BMC Res Notes; 2019 Jan; 12(1):8. PubMed ID: 30616681
[TBL] [Abstract][Full Text] [Related]
23. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant.
Zheng SR; Zheng HM; Qian SZ; Sang GW; Kaper RF
Contraception; 1999 Jul; 60(1):1-8. PubMed ID: 10549446
[TBL] [Abstract][Full Text] [Related]
24. Early implanon discontinuation and associated factors among women ever used implanon in Mettu district, Oromia regional state, southwest Ethiopia, 2021.
Tesfaye H; Negara E; Bayisa K
Reprod Health; 2021 Aug; 18(1):176. PubMed ID: 34454512
[TBL] [Abstract][Full Text] [Related]
25. Evidence of patients' challenges and barriers related to usage of Implanon®: scoping review protocol.
Prosad S; Mashamba-Thompson TP; Ojewole E
Syst Rev; 2018 Oct; 7(1):157. PubMed ID: 30309380
[TBL] [Abstract][Full Text] [Related]
26. The cost-effectiveness of a long-acting reversible contraceptive (Implanon) relative to oral contraception in a community setting.
Lipetz C; Phillips CJ; Fleming CF
Contraception; 2009 Apr; 79(4):304-9. PubMed ID: 19272500
[TBL] [Abstract][Full Text] [Related]
27. Magnitude and associated factors of early Implanon discontinuation among rural women in public health facilities of central Ethiopia: a community-based cross-sectional study.
Obsu M; Hundessa B; Garoma S; Aman H; Merga H
BMC Womens Health; 2022 Mar; 22(1):72. PubMed ID: 35287654
[TBL] [Abstract][Full Text] [Related]
28. Safety, efficacy and acceptability of implanon a single rod implantable contraceptive (etonogestrel) in University of Benin Teaching Hospital.
Aisien AO; Enosolease ME
Niger J Clin Pract; 2010 Sep; 13(3):331-5. PubMed ID: 20857796
[TBL] [Abstract][Full Text] [Related]
29. Level and Timing of Implanon Discontinuation and Associated Factors among Women Who Used Implanon in Andabet District, Public Health Facilities, North-West Ethiopia.
Dagnew GW; Gelaw YM; Asresie MB; Anteneh ZA
Biomed Res Int; 2021; 2021():6647660. PubMed ID: 34395623
[TBL] [Abstract][Full Text] [Related]
30. Contraceptive efficacy and side effects of Implanon.
Gezginc K; Balci O; Karatayli R; Colakoglu MC
Eur J Contracept Reprod Health Care; 2007 Dec; 12(4):362-5. PubMed ID: 17853166
[TBL] [Abstract][Full Text] [Related]
31. Implanon as a contraceptive choice for teenage mothers: a comparison of contraceptive choices, acceptability and repeat pregnancy.
Lewis LN; Doherty DA; Hickey M; Skinner SR
Contraception; 2010 May; 81(5):421-6. PubMed ID: 20399949
[TBL] [Abstract][Full Text] [Related]
32. One year study of Implanon on the adverse events and discontinuation.
Chaovisitsaree S; Piyamongkol W; Pongsatha S; Morakote N; Noium S; Soonthornlimsiri N
J Med Assoc Thai; 2005 Mar; 88(3):314-7. PubMed ID: 15962637
[TBL] [Abstract][Full Text] [Related]
33. Bone mineral density in women using the subdermal contraceptive implant Implanon for at least 2 years.
Pongsatha S; Ekmahachai M; Suntornlimsiri N; Morakote N; Chaovisitsaree S
Int J Gynaecol Obstet; 2010 Jun; 109(3):223-5. PubMed ID: 20206353
[TBL] [Abstract][Full Text] [Related]
34. A pilot efficacy study with a single-rod contraceptive implant (Implanon) in 200 Indonesian women treated for < or = 4 years.
Affandi B; Korver T; Geurts TB; Coelingh Bennink HJ
Contraception; 1999 Mar; 59(3):167-74. PubMed ID: 10382079
[TBL] [Abstract][Full Text] [Related]
35. The effects of Implanon on lipid metabolism in comparison with Norplant.
Suherman SK; Affandi B; Korver T
Contraception; 1999 Nov; 60(5):281-7. PubMed ID: 10717780
[TBL] [Abstract][Full Text] [Related]
36. [Acceptability of the etonogestrel-containing contraceptive implant (Implanon)].
Sergent F; Clamageran C; Bastard AM; Verspyck E; Marpeau L
J Gynecol Obstet Biol Reprod (Paris); 2004 Sep; 33(5):407-15. PubMed ID: 15480280
[TBL] [Abstract][Full Text] [Related]
37. Tolerability and clinical safety of Implanon.
Blumenthal PD; Gemzell-Danielsson K; Marintcheva-Petrova M
Eur J Contracept Reprod Health Care; 2008 Jun; 13 Suppl 1():29-36. PubMed ID: 18330815
[TBL] [Abstract][Full Text] [Related]
38. Etonogestrel implant (Implanon) for contraception.
Drug Ther Bull; 2001 Aug; 39(8):57-9. PubMed ID: 11526801
[TBL] [Abstract][Full Text] [Related]
39. Gaps in monitoring systems for Implanon NXT services in South Africa: An assessment of 12 facilities in two districts.
Pillay D; Morroni C; Pleaner M; Adeogba O; Chersich M; Naidoo N; Mullick S; Rees H
S Afr Med J; 2017 Oct; 107(10):827-831. PubMed ID: 29397799
[TBL] [Abstract][Full Text] [Related]
40. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting.
Lakha F; Glasier AF
Contraception; 2006 Oct; 74(4):287-9. PubMed ID: 16982226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
